Overview
Aducanumab’s withdrawn indication is recorded on the product page so history is not mistaken for a current option.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +6
- failures -3
Lecanemab is an infused antibody for early Alzheimer’s disease after amyloid is confirmed. It can cause brain swelling or bleeding on MRI and is not a cure.
Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option.
Similar pages
not linked directly; found by shared links- CompanyEisai
Shares CLARITY AD, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyAnti-amyloid antibodies
Shares Aducanumab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- RoadmapAnti-amyloid medicines
Shares ENGAGE, Aducanumab, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- Key paperLecanemab in Early Alzheimer’s Disease (CLARITY AD)
Shares CLARITY AD, Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TechnologyApoE testing
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- TermARIA
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- PairingLecanemab with MRI monitoring
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.
- IdeaAntibody trials that enrol mixed and comorbid disease
Shares Lecanemab, Alzheimer’s disease and the tag dementia-atlas.